Iniciar sesión Regístrese gratis

Last updated: 7 August 2024 at 4:10pm EST

Anne Cook Net Worth




The estimated Net Worth of Anne Marie Cook is at least $3.96 Millón dollars as of 10 May 2019. Ms. Cook owns over 15,700 units of Sage Therapeutics Inc stock worth over $5,243 and over the last 9 years she sold SAGE stock worth over $0. In addition, she makes $3,954,050 as Senior Vice President, General Counsel y Secretary at Sage Therapeutics Inc.

Ms. Cook SAGE stock SEC Form 4 insiders trading

Anne has made over 1 trades of the Sage Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 15,700 units of SAGE stock worth $468,802 on 10 May 2019.

The largest trade she's ever made was exercising 15,700 units of Sage Therapeutics Inc stock on 10 May 2019 worth over $468,802. On average, Anne trades about 714 units every 0 days since 2015. As of 10 May 2019 she still owns at least 700 units of Sage Therapeutics Inc stock.

You can see the complete history of Ms. Cook stock trades at the bottom of the page.





Anne Cook biography

Anne Marie Cook J,D, serves as Senior Vice President, General Counsel, Secretary of the Company. Prior to joining us, she served from December 2011 to September 2015 as Senior Vice President, General Counsel of Aegerion Pharmaceuticals, Inc., a biopharmaceutical company. From December 2008 to December 2011, Ms. Cook was a partner at the law firm Choate Hall & Stewart LLP, where she represented both private and public corporations in the life sciences industry in structuring and negotiating strategic transactions and providing general legal support in connection with the research, development and commercialization of pharmaceutical products. From April 2007 to December 2008, Ms. Cook was a Principal at the law firm Miller Canfield P.L.C. From September 2005 until April 2007, Ms. Cook served as General Counsel and Senior Vice President, Business and Corporate Development, and Secretary of ViaCell, Inc., a biotechnology company. Prior to joining ViaCell, Ms. Cook spent thirteen years at Biogen Idec Inc., most recently as Vice President, Chief Corporate Counsel. Ms. Cook holds a B.S. degree from Tufts University and a J.D. degree from the University of Notre Dame Law School.

What is the salary of Anne Cook?

As the Senior Vice President, General Counsel y Secretary of Sage Therapeutics Inc, the total compensation of Anne Cook at Sage Therapeutics Inc is $3,954,050. There are 3 executives at Sage Therapeutics Inc getting paid more, with Jeffrey Jonas having the highest compensation of $9,902,080.



How old is Anne Cook?

Anne Cook is 58, she's been the Senior Vice President, General Counsel y Secretary of Sage Therapeutics Inc since 2017. There are 8 older and 8 younger executives at Sage Therapeutics Inc. The oldest executive at Sage Therapeutics Inc is Dr. Jeffrey M. Jonas, 68, who is the Chief Innovation Officer, Chair of the Science & Technology Forum and Director.

What's Anne Cook's mailing address?

Anne's mailing address filed with the SEC is C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE, MA, 02142.

Insiders trading at Sage Therapeutics Inc

Over the last 10 years, insiders at Sage Therapeutics Inc have traded over $190,046,458 worth of Sage Therapeutics Inc stock and bought 150,092 units worth $6,260,297 . The most active insiders traders include Kevin P Starr, Robert Nelsen y Michael F Cola. On average, Sage Therapeutics Inc executives and independent directors trade stock every 32 days with the average trade being worth of $256,667. The most recent stock trade was executed by Kimi Iguchi on 2 January 2024, trading 1,642 units of SAGE stock currently worth $2,233.



What does Sage Therapeutics Inc do?

sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.



What does Sage Therapeutics Inc's logo look like?

Sage Therapeutics Inc logo

Complete history of Ms. Cook stock trades at Sage Therapeutics Inc

Fecha
#
Empresa
 Persona
Trans.
Transacción
 Acciones Precio por acción Precio total Acciones después de Fuente
10 May 2019 SAGE Sage Therapeutics Inc Anne Marie Cook
SVP, GC y Secretario
 Uso de opción 15,700 $29.86 $468,802
10 May 2019
700 ↗


Sage Therapeutics Inc executives and stock owners

Sage Therapeutics Inc executives and other stock owners filed with the SEC include: